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BB, 31% were due to failure to restart BB following hospitalization. More vigilance regard-
ing restoration of BB usage following hospital discharge is in order.
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Adverse Fatal and Nonfatal Outcomes in Both Reduced 
and Preserved Systolic Function Chronic Heart Failure: 
Findings From the Candesartan in Heart Failure 
Assessment of Reduction in Mortality and Morbidity 
Program (CHARM)
John J. McMurray, Chim C. Lang, Karl Swedberg, Jan Östergren, Christopher B. 
Granger, Eric Michelson, James B. Young, Bertil Olofsson, Mark Dunlap, Salim Yusuf, 
Marc A. Pfeffer, for the CHARM Investigators, Western Infirmary, Glasgow, United 
Kingdom
Background: Low hemoglobin (Hb) is associated with higher mortality in patients with
chronic heart failure (CHF) and a reduced left ventricular ejection fraction (LVEF).
Whether Hb is an independent predictor of survival and also predicts non-fatal outcomes
is unclear. The importance of Hb in CHF and preserved LVEF is unknown.
Methods: The 3 CHARM trials were: i) CHARM-Alternative (n= 2028): LVEF < 0.40 intol-
erant of an ACE inhibitor (ACE-I) ii) CHARM-Added (n=2548): LVEF < 0.40 taking an
ACE-I iii) CHARM-Preserved (n=3025): LVEF > 0.40. Patients were randomised to pla-
cebo or candesartan and followed for 37.7 months. Outcomes were compared in those
with Hb < and > median (13.6g/dL).
Results: Unadjusted outcomes are shown in the table. In a multivariate analysis Hb was
an independent predictor of outcomes in both reduced LVEF and preserved LVEF CHF.
For the 2 low LVEF trials combined, the hazard ratios (HR) for > median versus < median
Hb were: Death 0.62 95% CI (0.51-0.75) p<0.0001; CHF hospitalization 0.72 (0.60-0.86)
p=0.0005 and death or CHF hospitalization 0.68 (0.58-0.78) p<0.0001. For CHARM-Pre-
served the HR were: 0.63 (0.46-0.86) p=0.004, 0.62 (0.47-0.81) p=0.0005 and 0.65
(0.52-0.81) p=0.0002, respectively.
Outcome in overall CHARM Programme according to whether baseline haemoglo-
bin was above or equal to/below median 
Conclusion: Hb is an independent predictor not only of death but also of CHF hospital-
ization. Hb is of as much prognostic significance in CHF with preserved LVEF as in CHF 
with a reduced LVEF.
1108-110 Pulmonary Edema Prognostic Score: A Novel Simple 
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Marcin Fiutowski, Tomasz Waszyrowski, Maria Krzeminska-Pakula, Jaroslaw D. 
Kasprzak, Medical University of Lodz, Lodz, Poland, Jonscher Hospital, Lodz, Poland
BACKGROUND: Cardiogenic pulmonary edema (CPE) is a common reason of hospitali-
sation connected with high mortality, but few data are published regarding long- and
short-term prognosis and no prognostic scales are in use.
AIM: To establish a simple score predicting the in-hospital prognosis in patients with
CPE.
METHODS AND RESULTS: We studied 276 Pts (148 females; mean age 70 years) hos-
pitalised due to CPO (hospital stay 12±7 days). In-hospital mortality was 21%. 44 clinical
variables were included in the analysis to revealthe most significant mortality predictors:
acute myocardial infarction (RR=2,12), heart rate:>115/min. (RR=2,13), systolic blood
pressure < 130mmHg (RR=3,61) and white blood cells>11500/mm3 (RR=2,26) on pre-
sentation. The number of risk factors was summed to create pulmonary edema prognos-
tic score (PEPS). PEPS had a linear relationship with mortality - figure. Pts with PEPS 0
had very good short-term prognosis with 2% in-hospital mortality rate (RR=0,07)
whereas mortality in Pts with PEPS 4 was 64% (RR=3,31). Receiver operating character-
istic curve analysis proved good discriminative ability (AUC= 0,78). Score above 1 had
sensitivity of 79%, specificity of 62%, 36% positive and 92% negative predictive value for
in-hospital mortality
CONCLUSIONS: Pulmonary edema prognostic score is a simple bedside tool allowing a
precise prediction of in-hospital prognosis after acute cardiogenic pulmonary edema.
1108-111 Serum Hyaluronic Acid Elevation in Patients With 
Decompensated Congestive Heart Failure Is 
Independent of Left Ventricular Systolic Function
Leonardo C. Clavijo, Daniel J. Cantillon, Jinguo Chen, Lurong Zhang, Michael D. 
Greenberg, Cynthia M. Tracy, Georgetown University, Washington, DC
BACKGROUND: Hyaluronic acid (HA), an extracellular glycosaminoglycan, is elevated
during hepatic hypoperfusion, edema and fibroproliferative disorders. Serum HA is 90%
metabolized and excreted by the liver. We have recently demonstrated that serum HA is
elevated in patients (pts) with decompensated CHF (dCHF).
HYPOTHESIS: Serum HA elevation in pts with clinically dCHF is independent of LV sys-
tolic function (LVSF) and CHF etiology (ischemic vs. non-ischemic), thus reflecting poor
hepatic perfusion and edema.
METHODS: A novel enzyme linked immunosorbent assay (ELISA) was used to measure
serum HA levels in two hundred pts consecutively admitted to the hospital. Fourteen pts
were excluded due to chronic liver disease or renal insufficiency. All dCHF pts were
symptomatic and the diagnosis confirmed by a cardiologist blinded to HA level. Based on
LVSF measured by echocardiogram, gated nuclear imaging or ventriculogram dCHF pts
were divided in two groups: dCHF + preserved LVSF (EF>40%) or dCHF + depressed
LVSF (EF <40%). Ischemic cardiomyopathy was identified by the presence or absence of
coronary disease in the setting of dCHF.
RESULTS: Admission serum HA levels were markedly elevated in pts with dCHF (259.0
ng/ml, SEM=49.5, n=32) vs. non-CHF pts (104.0 ng/ml, SEM=6.2, n=154), p<0.001.
Serum HA levels in pts with dCHF + preserved LVSF (348.5 ng/ml, SEM=106.2, n=14)
and dCHF + depressed LVF (189.4 ng/ml, SEM=24.4, n=18) were elevated compare to
non-CHF pts (104.0 ng/ml, SEM=6.2, n=154), p<0.001. The difference between dCHF
with preserved and depressed LVSF was not significant (p=0.11). There was no differ-
ence in HA levels between ischemic and non-ischemic dCHF groups (293.3 ng/ml,
SEM=71.9, n=21 vs. 193.3 ng/ml, SEM=41.3, n=11), p=0.27.
CONCLUSION: Serum hyaluronic acid level is elevated in pts with symptomatic clinically
dCHF. HA elevation is independent of left ventricular systolic function and ischemic etiol-
ogy. Further studies are needed to investigate the mechanisms and prognostic value of
HA elevation during dCHF.
1108-112 An Embolic Event to Death in More Than 50 Percent of 
Patients With Idiopathic Dilated Cardiomyopathy in End- 
Stage Heart Failure
Antonio C. Barretto, Sr., Mucio T. Oliveira Jr, Sr., Robinson T. Munhoz, Sr., Airton R. 
Scipioni, Sr., Maria L. Higuchi, Jose A F Ramires, Sr., Heart Institute, (InCor), University 
of São Paulo Medical School, São Paulo, Brazil
Background: Pts with idiopathic dilated cardiomyopathy (IDC) and end stage heart failure
has a worse prognosis with high mortality. Embolic events (EE) could contribute to the
heart failure bad evolution of these pts.
Objective: To clarify the importance of EE in the evolution of pts with IDC, we analyzed
the data from necropsies of heart failure pts that died at the hospital in the last ten years.
Methods: Between 1990 and 1999, 3847 necropsies were performed and 118 pts had
IDC. The pts mean age was 41.8 years and 74 (62,7%) were male. The echocardiogram
showed a mean LV end diastolic diameter of 76,0 mm and a mean LV ejection fraction of
0,32. Results: EE were identified in 90 (76,3%) pts, 61 (51,7%) of those had pulmonary
embolism (PE), 29 (24,6%) systemic embolism (SE) and 33 (14.2%) both. The great
majority of EE was not diagnosis in life. Cardiac thrombus was detected in right cham-
bers in 26 pts (22,0%) and in left chambers in 18 (24,62%). The main embolic source
Hb > median
(n=1368)
Hb <
median
(n=1281)
Outcome (%)
death 19.0 27.9
CHF hospitalization 22.5 30.3
Death or CHF hospitalization 33.5 44.9
